Drugs for Common Variable Immunodeficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 89)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Rifaximin |
Approved, Investigational |
Phase 4 |
|
80621-81-4 |
46783403 6436173 |
Synonyms:
(7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,23,36-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6-oxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.1,.0,.0,.0,]heptatriaconta-1(35),2,4,9,19,21,23,25(36),26(34),28,30,32-dodecaen-13-yl acetic acid
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
NORMIX
Redactiv
RIFACOL
RIFAMYCIN L 105
RIFAMYCIN L 105SV
RIFAXIDIN
Rifaximin
|
RIFAXIMINA
RIFAXIMINE
RIFAXIMINUM
RIFAXIMINUN
TARGAXAN
Xifaxan
XIFAXANTA
XIFAXSAN
|
|
2 |
|
Budesonide |
Approved |
Phase 4 |
|
51333-22-3 |
5281004 40000 63006 |
Synonyms:
(11b,16a)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11Β,16α)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
AIRCORT
Bidien
BUDEFLAM AQUANASE
BUDELIN NOVOLIZER
BUDENOFALK
Budeson
Budesónida
BUDESONIDE
Budesonide, (R)-isomer
Budesonide, (S)-isomer
Budicort
CORTIMENT
Cortivent
Desowen
DEXBUDESONIDE
DUORESP SPIROMAX
ENTOCORT
ENTOCORT CR
Entocort ec
Entocort®|Eohilia® (budesonide oral suspension)|Jorveza®|Pulmicort®|S-1320|Uceris®
Horacort
MAP0010
|
MAP-0010
Micronyl
Noex
ORTIKOS
PREFERID
PULMAXAN
Pulmicort
PULMICORT FLEXHALER
PULMICORT L.S.
Pulmicort Nebuamp
PULMICORT RESPULES
Pulmicort Turbuhaler
R01AD05
Rhinocort
RHINOCORT ALLERGY
RHINOCORT AQUA
RHINOCORT AQUA 64
Rhinocort Turbuhaler
Rhinosol
S-1320
Spirocort
SYMBICORT
Tridesilon
Uceris
|
|
3 |
|
Immunoglobulin G |
|
Phase 4 |
|
|
|
4 |
|
Complement System Proteins |
|
Phase 4 |
|
|
|
5 |
|
Complement C1s |
|
Phase 4 |
|
|
|
6 |
|
Complement C1 Inhibitor Protein |
|
Phase 4 |
|
|
|
7 |
|
Complement C1 Inactivator Proteins |
|
Phase 4 |
|
|
|
8 |
|
Immunoglobulins, Intravenous |
|
Phase 4 |
|
|
|
9 |
|
gamma-Globulins |
|
Phase 4 |
|
|
|
10 |
|
Rho(D) Immune Globulin |
|
Phase 4 |
|
|
|
11 |
|
Hormones |
|
Phase 4 |
|
|
|
12 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
13 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
14 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
15 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
16 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
17 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
18 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
19 |
|
Antibodies |
|
Phase 3 |
|
|
|
20 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
21 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 2 |
|
198153-51-4 |
|
Synonyms:
PEGASYS
PEG-IFN alfa-2A
PEG-Interferon alfa-2A
PEGINTERFERON ALFA-2A
PEGYLATED IFN-ALPHA-2A
Pegylated Interfeaon alfa-2A
|
Pegylated interferon alfa-2a
Pegylated interferon alpha-2a
Pegylated-interferon alfa 2a
RO-258310000
ROFERON-A
|
|
22 |
|
Ustekinumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
815610-63-0 |
|
Synonyms:
CNTO-1275
STELARA
STELERA
|
|
|
23 |
|
Alemtuzumab |
Approved, Investigational |
Phase 2 |
|
216503-57-0 |
|
Synonyms:
ALEMTUZUMAB
ALEMTUZUMAB (GENETICAL RECOMBINATION)
CAMPATH
campath 1H|Campath®|campath-1H|Lemtrada®
CAMPATH MABCAMPATH
CAMPATH MABCAMPATH, LEMTRADA
|
CAMPATH-1H
GZ402673
GZ-402673
LDP-03
LEMTRADA
MABCAMPATH
|
|
24 |
|
Mycophenolic acid |
Approved, Investigational |
Phase 2 |
|
24280-93-1 |
446541 |
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
68618
Acid, mycophenolic
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Cellcept
ERL080
ERL-080
ERL-080|Myfortic® (mycophenolate sodium)
Melbex
Micofenolico acido
Mofetil hydrochloride, mycophenolate
Mofetil, mycophenolate
|
Mycophenoic acid
Mycophenolate
Mycophenolate mofetil
Mycophenolate mofetil hydrochloride
Mycophenolate sodium
Mycophenolate, sodium
MYCOPHENOLIC ACID
Mycophenolic acid morpholinoethyl ester
Mycophenolsaeure
Mycophenolsäure
Myfortic
NSC-129185
RS-61443 [AS MOFETIL]
Sodium mycophenolate
|
|
25 |
|
Tacrolimus |
Approved, Investigational |
Phase 2 |
|
104987-11-3 |
6473866 445643 |
Synonyms:
(-)-FK 506
Anhydrous tacrolimus
Anhydrous, tacrolimus
Cilag brand OF tacrolimus
FK5
FK506
FK-506
FK506|fujimycin|Prograf®|Protopic®
FR-900506
FUJIMYCIN
Fujisawa brand OF tacrolimus
Janssen brand OF tacrolimus
|
K506
LCP-Tacro
Prograf
Prograft
PROTOPIC
Tacarolimus
TACROLIMUS
Tacrolimus anhydrous
tacrolimus hydrate
TACROLIMUS MONOHYDRATE
Tacrolimus, anhydrous
|
|
26 |
|
Benzocaine |
Approved, Investigational |
Phase 2 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
27 |
|
Tannic acid |
Approved |
Phase 2 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
28 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
29 |
|
Pentostatin |
Approved, Investigational |
Phase 2 |
|
53910-25-1 |
439693 |
Synonyms:
2' Deoxycoformycin
2'-DCF
2'-Deoxycoformycin
2'-deoxycoformycin|deoxycoformycin|Nipent®
2'-Dexoycoformycin
CI-825
Co vidarabine
CO-Vidarabine
Deoxycoformycin
Lederle brand OF pentostatin
Nipent
|
NSC-218321
PD-81565
Pentostatin
PENTOSTATINA
PENTOSTATINE
PENTOSTATINUM
Prasfarma brand OF pentostatin
Supergen brand OF pentostatin
Warner-lambert brand OF pentostatin
Wyeth brand OF pentostatin
YK-176
|
|
30 |
|
Coenzyme M |
Approved, Investigational |
Phase 2 |
|
3375-50-6 |
598 23662354 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-Mercaptoethanesulphonic acid
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzym m
Coenzyme m
CoM
D-7093
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
NSC-113891
Reduced coenzyme m
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Î’-mercaptoethanesulfonate
Î’-mercaptoethanesulfonic acid
Î’-mercaptoethanesulphonate
Î’-mercaptoethanesulphonic acid
|
|
31 |
|
Melphalan |
Approved |
Phase 2 |
|
148-82-3 |
4053 460612 |
Synonyms:
2-Amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate
2-Amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoate
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
AIKERAN
ALANINE NITROGEN MUSTARD
Alkeran
CB-3025
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
L-PAM
L-Phenylalanine mustard
L-PHENYLALANINE MUSTARD (L-PAM)
L-SARCOLYSIN
L-Sarcolysine
L-Sarkolysin
Medphalan
MELFALAN
Melfalano
Melphalan
|
Melphalanum
Mephalan
Merphalan
MLP673
Mustard, phenylalanine
NCI-C04853
NSC-241286
NSC-8806
p-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
p-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
p-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
Sarcolysin
Sarcolysine
Sarkolysin
SK 15673
SK-15673
|
|
32 |
|
Abatacept |
Approved |
Phase 2 |
|
332348-12-6 |
|
Synonyms:
ABATACEPT
ABATACEPT (GENETICAL RECOMBINATION)
Abatacept recombinant
BMS-188667
BMS-188667|CTLA4-IgG4m|Orencia®|RG-1046|RG-2077
CTLA4IG
CTLA4-IG
|
CTLA4IGG4M
CTLA4-IGG4M
ORENCIA
ORENCIA CLICKJECT
RG-1046
RG-2077
|
|
33 |
|
Busulfan |
Approved, Investigational |
Phase 1, Phase 2 |
|
55-98-1 |
2478 |
Synonyms:
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Dimesyloxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulphonoxybutane
Bisulfex
Bisulphex
BUSILVEX
BUSULFAN
Busulfan glaxosmithkline brand
Busulfan orphan brand
Busulfan wellcome
Busulfan wellcome brand
Busulfano
Busulfanum
Busulfex
BUSULFEX IV
Busulphan
Busulphane
Busulphano
Busulphanum
Butanedioldimethanesulfonate
Buzulfan
Citosulfan
Glaxo wellcome brand OF busulfan
GlaxoSmithKline brand OF busulfan
Glyzophrol
Leucosulfan
|
Leucosulphan
Mablin
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
Myeleukon
Myeloleukon
Myelosan
Mylecytan
Myleran
Myléran
Myleran Tablets
N-Butane-1,3-di(methylsulfonate)
NCI-C01592
NSC-750
Orphan brand OF busulfan
Sulfabutin
Sulphabutin
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene dimethane sulfonate
Tetramethylenester kyseliny methansulfonove
Wellcome brand OF busulfan
Wellcome, busulfan
|
|
34 |
|
Fludarabine |
Approved |
Phase 1, Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
35 |
|
Thiotepa |
Approved, Investigational |
Phase 1, Phase 2 |
|
52-24-4 |
5453 |
Synonyms:
Girostan
NSC-6396
Rethio
Tepadina
Tepadina®|Thioplex®
Tespa
Tespamin
Thio tepa
|
Thiophosphamide
Thioplex
Thio-tepa
THIOTEPA
THIOTEPA 或 THIOTEPA
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
36 |
|
Fisetin |
Experimental |
Phase 2 |
|
528-48-3 |
|
Synonyms:
2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one
3,3',4',7-Tetrahydroxyflavone
3,7,3',4'-tetrahydroxyflavone
|
5-Desoxyquercetin
7,3',4'-Trihydroxyflavonol
NSC-407010
|
|
37 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
38 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
39 |
|
Interferon alpha-2 |
|
Phase 2 |
|
|
|
40 |
|
interferons |
|
Phase 2 |
|
|
|
41 |
|
Interferon-alpha |
|
Phase 2 |
|
|
|
42 |
|
Dermatologic Agents |
|
Phase 1, Phase 2 |
|
|
|
43 |
|
Interleukin-12 |
|
Phase 1, Phase 2 |
|
|
|
44 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
45 |
|
Antitubercular Agents |
|
Phase 2 |
|
|
|
46 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
47 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
48 |
|
Immune Checkpoint Inhibitors |
|
Phase 2 |
|
|
|
49 |
|
Alkylating Agents |
|
Phase 1, Phase 2 |
|
|
|
50 |
|
Antineoplastic Agents, Alkylating |
|
Phase 1, Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 51)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effects of Rifaximin, by Modulation of the Gut Microbiota, on Markers of Systemic Inflammation in Patients With Common Variable Immunodeficiency - An Exploratory Open-label Randomized Controlled Trial |
Completed |
NCT01946906 |
Phase 4 |
Rifaximin |
2 |
A Multicenter Study on the Efficacy and Safety of Vivaglobin® in Previously Untreated Patients (PUPs) With Primary Immunodeficiency (PID) |
Completed |
NCT00520494 |
Phase 4 |
Vivaglobin |
3 |
A Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions |
Completed |
NCT03576469 |
Phase 4 |
|
4 |
A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents |
Completed |
NCT01289847 |
Phase 4 |
|
5 |
A Prospective Study of the Utility of Spirometry to Identify and Manage Immunoglobulin Replacement Dosage in Primary Antibody Deficiency in Patients With Potentially Reversible Airway Disease |
Not yet recruiting |
NCT05193552 |
Phase 4 |
Hizentra |
6 |
Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies |
Terminated |
NCT03866538 |
Phase 4 |
Withdrawal of Oral Budesonide |
7 |
A Multicentre Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency |
Completed |
NCT00542997 |
Phase 3 |
|
8 |
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases |
Completed |
NCT01963143 |
Phase 3 |
|
9 |
A Phase III, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subgam-VF in Primary Immunodeficiency Diseases |
Completed |
NCT01884311 |
Phase 3 |
|
10 |
An Open Study to Evaluate the Safety and Efficacy of IVIG-F10 in Patients With Primary Immunodeficiency Diseases (PID) |
Completed |
NCT00168012 |
Phase 3 |
Immunoglobulins Intravenous (Human) |
11 |
A Multicenter Study on the Efficacy, Safety and Pharmacokinetics of IgPro10 in Patients With Primary Immunodeficiency (PID) |
Completed |
NCT00168025 |
Phase 3 |
Immunoglobulins Intravenous (Human) |
12 |
A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID) |
Completed |
NCT00322556 |
Phase 3 |
Immunoglobulins Intravenous (Human) |
13 |
IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients |
Completed |
NCT00220766 |
Phase 3 |
Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water |
14 |
An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Subject, Investigator and Sponsor Blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 (Leniolisib) in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/ p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency) |
Completed |
NCT02435173 |
Phase 2, Phase 3 |
CDZ173 |
15 |
A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam® Given Via the Subcutaneous Route in Primary Antibody Deficient Patients. |
Completed |
NCT02247141 |
Phase 3 |
|
16 |
A Phase III, Multicenter, Open-Label Study To Evaluate The Efficacy, Safety, and Pharmacokinetics of Gammaplex® in Primary Immunodeficiency Diseases |
Completed |
NCT00278954 |
Phase 3 |
|
17 |
Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial |
Unknown status |
NCT02661477 |
Phase 2 |
pegylated interferon alfa 2 |
18 |
An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency |
Completed |
NCT02199496 |
Phase 1, Phase 2 |
|
19 |
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity |
Recruiting |
NCT04339777 |
Phase 2 |
Busulfan test dose;Fludarabine;Busulfan;Alemtuzumab;Tacrolimus (Tacro);Mycophenolate mofetil (MMF);Cyclophosphamide (Cytoxan) |
20 |
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies |
Recruiting |
NCT02579967 |
Phase 2 |
Immunosuppression Only Conditioning -Closed with amendment L;Reduced Intensity Conditioning;Myeloablative Conditioning-Closed with amendment L;GVHD Prophylaxis |
21 |
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation |
Recruiting |
NCT03663933 |
Phase 2 |
Immunosuppression Only Conditioning;Reduced Intensity Conditioning;GVHD Prophylaxis |
22 |
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease |
Recruiting |
NCT04925375 |
Phase 2 |
Abatacept |
23 |
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime |
Recruiting |
NCT01821781 |
Phase 2 |
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan |
24 |
PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders |
Active, not recruiting |
NCT03513328 |
Phase 1, Phase 2 |
Thiotepa--single daily dose;Thiotepa--escalated dose |
25 |
Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors |
Enrolling by invitation |
NCT01852370 |
Phase 1, Phase 2 |
|
26 |
Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID) |
Not yet recruiting |
NCT05593588 |
Phase 2 |
Fisetin;Placebo |
27 |
Randomised, Multicentric, Phase ii Study of the Immunogenicity of a "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency |
Terminated |
NCT01489618 |
Phase 2 |
|
28 |
Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID) |
Withdrawn |
NCT02789397 |
Phase 2 |
Rituximab (RTX) and Azathioprine (AZA);Placebos |
29 |
A Pilot Study of Safety and Efficacy of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency |
Completed |
NCT00263237 |
Phase 1 |
STA-5326 |
30 |
Investigation of the Lymphocyte Surface Expression of Patients With Primary Immunodeficiency (Common Variable Immunodeficiency (CVID)), Compared to Controls |
Unknown status |
NCT01196702 |
|
|
31 |
Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD) Diagnosed in Children and Young Adults With Common Variable Immunodeficiency |
Unknown status |
NCT03648567 |
|
|
32 |
Investigation of Molecular, Genetic and Cellular Mechanisms of Human Immune Disorders and Deficiencies |
Unknown status |
NCT01981785 |
|
|
33 |
Consequences of DNA Repair and Telomere Defects on the Function of the Immune System: Application to CVID and Immune Deficiencies With Dysmorphic Syndromes |
Unknown status |
NCT02556359 |
|
|
34 |
Serum IgG Antibody to Streptococcus Pneumoniae, Haemophilus Influenzae Type b and Tetanus Toxoid in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin Infusions |
Completed |
NCT00661401 |
|
|
35 |
Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency |
Completed |
NCT00004695 |
|
PEG-interleukin-2 |
36 |
Retrospective Study of the Breadth of Donor Options for Patients With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide |
Completed |
NCT03188419 |
|
|
37 |
The Immune Basis for the Gastrointestinal Complications of Common Variable Immunodeficiency |
Completed |
NCT00015431 |
|
|
38 |
The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease |
Completed |
NCT03211689 |
|
|
39 |
Effects of Intravenous Human Polyclonal Immunoglobulins G Infusion on Endothelial Function and Insulin Sensitivity in Humans |
Completed |
NCT03534479 |
|
Polyclonal IgG |
40 |
Phenotype-genotype Correlation in a Sub-population of Severe Primary Immunodeficiency With Lymphoproliferation and Neutropenia |
Completed |
NCT03427593 |
|
|
41 |
Construction and Validation of a Health-related Quality of Life (HR-QOL) Instrument for Patients With Primary Antibody Deficiency Disease |
Completed |
NCT02542228 |
|
|
42 |
Natural History of Bronchiectasis |
Recruiting |
NCT00943514 |
|
|
43 |
Vaccine-induced SARS-CoV-2-specific T Cell Responses in Patients With Primary Immune Deficiency Disease |
Recruiting |
NCT05321407 |
|
|
44 |
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies |
Recruiting |
NCT01652092 |
|
Alemtuzumab 0.3 mg;Cyclophosphamide;Busulfan;Fludarabine phosphate 40 mg;Melphalan;Alemtuzumab 0.2 mg;Fludarabine phosphate 30 mg;MESNA |
45 |
Studies of Immune Regulation in Patients With Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes |
Recruiting |
NCT00001244 |
|
|
46 |
Improving the Diagnosis of Common Variable Immune Deficiency by Analysis of Innate and Adaptive Signaling Pathways |
Active, not recruiting |
NCT03335605 |
|
|
47 |
Early Detection of Primary Antibody Deficiencies in Primary Care Facilities by an Algorithm Driven Selection of Serologic Testing in Individuals at Risk. |
Active, not recruiting |
NCT05310604 |
|
|
48 |
A Randomized Study Evaluating Set-up Reproducibility Using Cone Beam CT (CBCT) With and Without a Customized Vacuum Immobilization Device (CVID) in Rectal Cancer Patients Treated With Preoperative Pelvic Radiation Therapy |
Active, not recruiting |
NCT00937248 |
|
|
49 |
Composition and Function of Gut Microbiota in Porto-sinusoidal Vascular Disease Associated With Variable Common Immunodeficiency |
Not yet recruiting |
NCT05481554 |
|
|
50 |
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies |
Terminated |
NCT00006054 |
|
anti-thymocyte globulin;busulfan;cyclophosphamide;cyclosporine;etoposide;methotrexate;methylprednisolone;prednisone |
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Common Variable Immunodeficiency:
Embryonic/Adult Cultured Cells Related to Common Variable Immunodeficiency:
|